Engineered immune cells take on bladder cancer in early trial

NCT ID NCT03185468

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new type of immunotherapy called 4SCAR-T cells in 20 people with advanced bladder cancer that has spread and no longer responds to standard treatments. The cells are genetically modified to recognize and attack cancer cells. The study aims to see if this approach is safe and can help patients live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 4SCAR-T cells (genetically modified immune cells targeting PSMA and FRa proteins)
What this could lead to: If it works, this could point toward a new treatment option for advanced bladder cancer when other therapies have failed.
What could go wrong: This is a very early Phase I/II trial with only 20 participants, so results may not apply broadly. Cell therapies can cause severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER UROTHELIAL CARCINOMA BLADDER

Contacts and locations

Locations

Shenzhen Geno-immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.